Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
About this episode
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
(00:32)
Could you give us a brief overview about your background and yourself?
(02:16)
Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?
(05:34)
What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?
(08:01)
Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?
(10:36)
Could you elaborate on the specific clinical indications for testing in relation to irinotecan?
(13:27)
How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?
(14:02)
Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?
Get every episode summarized
Each time Answers from the Lab publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Answers from the Lab
Closing a Diagnostic Gap for Chronic Diarrhea
Answers from the Lab
Unlock the Full Potential of Research Data
Answers from the Lab
A New Mindset for Leading Through Change
Answers from the Lab
Key Components of Innovation Success
Answers from the Lab